Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
ACRV Stock Chart & Stats
$2.36
-$0.20(-3.17%)
At close: 4:00 PM EST
$2.36
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.05 - $8.00
Previous CloseN/A
Volume1.72K
Average Volume (3M)978.16K
Market Cap
$74.47M
Enterprise Value-$56.47M
Total Cash (Recent Filing)$129.25M
Total Debt (Recent Filing)$2.99M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 26, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding31,555,126
10 Day Avg. Volume744,277
30 Day Avg. Volume978,160
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)11.51
Price to Sales (P/S)0.00
P/FCF Ratio-29.72
Enterprise Value/Market Cap-0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.52
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$10.60Price Target Upside349.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.01
Revenue Forecast (FY)$145.50K
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignThe elimination of the pre-treatment biopsy requirement in Arm 3 should meaningfully accelerate screening-to-enrollment conversion rates by reducing patient hesitancy.
Drug EfficacyThe reported cORR of 35% is encouraging compared to 2L therapies with 10-15% ORR, demonstrating high potential for superiority over standard of care chemotherapy.
Financial PositionThe company ended the recent period with $134.4 million in cash and investments, providing sufficient resources to advance its clinical programs.
Bears Say
Past Licensing ChallengesACR-368 was in-licensed from Lilly following a failure to meet target efficacy levels of 30%-40%.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.05 and its highest was $8.00 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $74.47M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 118 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.591 by $0.121.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,555,126 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.591. Following the earnings report the stock price went up 8.213%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.60 (349.15% Upside)
$10.60 (349.15% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 322.2%
Last 30 Days ▲ 322.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-67.89%
12-Months-Change
Fundamentals
Return on Equity
-50.23%
Trailing 12-Months
Asset Growth
-32.32%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$10.60
▲(349.15% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
44.65% Insiders
2.44% Mutual Funds
6.80% Other Institutional Investors
43.74% Public Companies and Individual Investors
Options Prices
Currently, No data available
---